Targeting NSCLC with Uncommon EGFR Mutations

Expert perspectives on treatment options for patients with uncommon EGFR mutations in non–small cell lung cancer.

EP. 1: Optimal Molecular Testing Strategies in Non–Small Cell Lung Cancer

June 29th 2022

Expert perspectives on the current landscape of molecular profiling in patients with non–small cell lung cancer.

EP. 2: Overview of EGFR-Mutated Non–Small Cell Lung Cancer

June 29th 2022

Insight on EGFR-mutated non–small cell lung cancer’s impact on treatment options and overall patient prognoses.

EP. 3: Targeting Rare EGFR Mutations in NSCLC: Afatinib and Mobocertinib

July 6th 2022

Sandip Patel, MD, highlights the use of afatinib and mobocertinib, respectively, to treat NSCLC with rare EGFR-mutation variants.

EP. 4: EGFR-Targeted Therapy in NSCLC: Optimizing Sequencing and Combinations

July 6th 2022

Focusing on the broader treatment armamentarium for EGFR-mutated NSCLC, Sandip Patel, MD, considers possible sequencing and combination strategies.

EP. 5: Improving Targeted Therapeutics in NSCLC Management

July 12th 2022

Before closing out his discussion on NSCLC, Sandip Patel, MD, shares his excitement for evolving targeted strategies and improved patient outcomes.

EP. 6: Overview of Actionable Mutations and Molecular Profiling in NSCLC

July 12th 2022

Expert oncologist Roy Herbst, MD, PhD, provides a comprehensive overview of actionable mutations and molecular profiling in NSCLC.

EP. 7: Optimizing Use of Molecular Testing in Non–Small Cell Lung Cancer

July 19th 2022

Expert perspectives on molecular profiling strategies that may help overcome barriers to testing in non–small cell lung cancer.

EP. 8: Understanding the Impact of EGFR Mutations on NSCLC Management

July 19th 2022

Roy Herbst, MD, PhD, provides insight on the importance of EGFR mutations, both common and rare, in patients with non–small cell lung cancer.

EP. 9: Novel Agents Targeting EGFR Mutations in Non–Small Cell Lung Cancer

July 27th 2022

Considerations for use of novel EGFR-targeted agents osimertinib, amivantamab, and poziotinib in NSCLC, in the context of respective clinical trial data.

EP. 10: Optimizing Sequencing of Novel EGFR-Targeted Agents in NSCLC

July 27th 2022

Closing out his discussion on actionable mutations in NSCLC, Roy Herbst, MD, PhD, discusses optimal sequencing of EGFR-targeted agents.